nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Abacavir—acquired immunodeficiency syndrome	0.35	0.542	CbGbCtD
Naltrexone—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0494	0.0766	CbGbCtD
Naltrexone—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0447	0.0693	CbGbCtD
Naltrexone—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0386	0.0598	CbGbCtD
Naltrexone—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0374	0.0581	CbGbCtD
Naltrexone—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0339	0.0525	CbGbCtD
Naltrexone—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0339	0.0525	CbGbCtD
Naltrexone—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0325	0.0503	CbGbCtD
Naltrexone—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0251	0.0389	CbGbCtD
Naltrexone—OPRM1—nerve—acquired immunodeficiency syndrome	0.00339	0.149	CbGeAlD
Naltrexone—UGT1A1—blood plasma—acquired immunodeficiency syndrome	0.00326	0.143	CbGeAlD
Naltrexone—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00126	0.0272	CbGpPWpGaD
Naltrexone—UGT1A1—digestive system—acquired immunodeficiency syndrome	0.00125	0.0551	CbGeAlD
Naltrexone—UGT1A1—blood—acquired immunodeficiency syndrome	0.00119	0.0525	CbGeAlD
Naltrexone—OPRD1—nervous system—acquired immunodeficiency syndrome	0.00112	0.0491	CbGeAlD
Naltrexone—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.0011	0.0238	CbGpPWpGaD
Naltrexone—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.00108	0.0473	CbGeAlD
Naltrexone—OPRK1—nervous system—acquired immunodeficiency syndrome	0.00107	0.0471	CbGeAlD
Naltrexone—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.00103	0.0454	CbGeAlD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000975	0.0211	CbGpPWpGaD
Naltrexone—OPRM1—blood—acquired immunodeficiency syndrome	0.000939	0.0413	CbGeAlD
Naltrexone—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000931	0.0201	CbGpPWpGaD
Naltrexone—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000904	0.0398	CbGeAlD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000855	0.0185	CbGpPWpGaD
Naltrexone—OPRD1—brain—acquired immunodeficiency syndrome	0.000854	0.0376	CbGeAlD
Naltrexone—OPRK1—brain—acquired immunodeficiency syndrome	0.000819	0.036	CbGeAlD
Naltrexone—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000762	0.0335	CbGeAlD
Naltrexone—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000739	0.0325	CbGeAlD
Naltrexone—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000734	0.0323	CbGeAlD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000722	0.0156	CbGpPWpGaD
Naltrexone—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000702	0.0152	CbGpPWpGaD
Naltrexone—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00066	0.0143	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000654	0.0142	CbGpPWpGaD
Naltrexone—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000615	0.0133	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000591	0.0128	CbGpPWpGaD
Naltrexone—OPRM1—brain—acquired immunodeficiency syndrome	0.000583	0.0256	CbGeAlD
Naltrexone—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000578	0.0125	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000573	0.0124	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000534	0.0116	CbGpPWpGaD
Naltrexone—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00052	0.0113	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000518	0.0112	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000498	0.0108	CbGpPWpGaD
Naltrexone—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000489	0.0106	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000485	0.0105	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000468	0.0101	CbGpPWpGaD
Naltrexone—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000452	0.00979	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000438	0.00948	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000437	0.00945	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000427	0.00924	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000427	0.00924	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000415	0.00899	CbGpPWpGaD
Naltrexone—ABCB1—retina—acquired immunodeficiency syndrome	0.000405	0.0178	CbGeAlD
Naltrexone—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000396	0.00858	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000396	0.00858	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000396	0.00857	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000369	0.00799	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000365	0.0079	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000358	0.00776	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000347	0.00752	CbGpPWpGaD
Naltrexone—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000335	0.00725	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00033	0.00714	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000326	0.00706	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00032	0.00693	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000314	0.0068	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.000313	0.00678	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00031	0.00672	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00031	0.00672	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000302	0.00653	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000294	0.00636	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	0.00029	0.00627	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000289	0.00626	CbGpPWpGaD
Naltrexone—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000288	0.0127	CbGeAlD
Naltrexone—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.000287	0.0062	CbGpPWpGaD
Naltrexone—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000284	0.0125	CbGeAlD
Naltrexone—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000278	0.00603	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000273	0.00591	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000272	0.00589	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000272	0.00589	CbGpPWpGaD
Naltrexone—ABCB1—blood—acquired immunodeficiency syndrome	0.000271	0.0119	CbGeAlD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00027	0.00585	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000266	0.00575	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000265	0.00573	CbGpPWpGaD
Naltrexone—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000262	0.0115	CbGeAlD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000262	0.00567	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000262	0.00567	CbGpPWpGaD
Naltrexone—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000261	0.0115	CbGeAlD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000258	0.00559	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000256	0.00553	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	0.000251	0.00544	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	0.000251	0.00544	CbGpPWpGaD
Naltrexone—ABCB1—vagina—acquired immunodeficiency syndrome	0.000251	0.011	CbGeAlD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000245	0.0053	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000245	0.00529	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000244	0.00528	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000243	0.00526	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000239	0.00518	CbGpPWpGaD
Naltrexone—ABCB1—lung—acquired immunodeficiency syndrome	0.000237	0.0104	CbGeAlD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000236	0.00511	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00023	0.00498	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00023	0.00498	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00023	0.00497	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00023	0.00497	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000227	0.0049	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000224	0.00485	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000224	0.00484	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000221	0.00479	CbGpPWpGaD
Naltrexone—ABCB1—nervous system—acquired immunodeficiency syndrome	0.00022	0.00966	CbGeAlD
Naltrexone—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	0.000218	0.00471	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000215	0.00465	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000213	0.00461	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000213	0.0046	CbGpPWpGaD
Naltrexone—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000212	0.0093	CbGeAlD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	0.000211	0.00457	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000208	0.00451	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000208	0.00451	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000207	0.00448	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000206	0.00447	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000202	0.00438	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000199	0.00431	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000194	0.0042	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000194	0.0042	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000194	0.0042	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000191	0.00414	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000189	0.0041	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000186	0.00404	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000186	0.00403	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000182	0.00395	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000182	0.00395	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000181	0.00393	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00018	0.0039	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.00018	0.00389	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000179	0.00388	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000175	0.00379	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000175	0.00378	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000169	0.00365	CbGpPWpGaD
Naltrexone—ABCB1—brain—acquired immunodeficiency syndrome	0.000168	0.00739	CbGeAlD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000166	0.0036	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	0.000165	0.00357	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	0.000165	0.00357	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000164	0.00355	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000163	0.00354	CbGpPWpGaD
Naltrexone—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000162	0.00714	CbGeAlD
Naltrexone—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	0.00016	0.00347	CbGpPWpGaD
Naltrexone—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00016	0.000558	CcSEcCtD
Naltrexone—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000159	0.000557	CcSEcCtD
Naltrexone—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000159	0.000557	CcSEcCtD
Naltrexone—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000159	0.000556	CcSEcCtD
Naltrexone—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000159	0.000556	CcSEcCtD
Naltrexone—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000159	0.000555	CcSEcCtD
Naltrexone—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000159	0.000555	CcSEcCtD
Naltrexone—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000159	0.000554	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000158	0.00343	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000158	0.00343	CbGpPWpGaD
Naltrexone—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000158	0.000554	CcSEcCtD
Naltrexone—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000158	0.000554	CcSEcCtD
Naltrexone—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000158	0.000554	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000158	0.00343	CbGpPWpGaD
Naltrexone—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000158	0.000552	CcSEcCtD
Naltrexone—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000158	0.000552	CcSEcCtD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000158	0.00341	CbGpPWpGaD
Naltrexone—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000157	0.00055	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000157	0.00055	CcSEcCtD
Naltrexone—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000157	0.00341	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	0.000157	0.0034	CbGpPWpGaD
Naltrexone—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000157	0.000548	CcSEcCtD
Naltrexone—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000157	0.000547	CcSEcCtD
Naltrexone—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000157	0.000547	CcSEcCtD
Naltrexone—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000157	0.000547	CcSEcCtD
Naltrexone—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000157	0.000547	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000156	0.000546	CcSEcCtD
Naltrexone—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000156	0.000546	CcSEcCtD
Naltrexone—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000156	0.000546	CcSEcCtD
Naltrexone—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000155	0.000543	CcSEcCtD
Naltrexone—Pain—Indinavir—acquired immunodeficiency syndrome	0.000155	0.000543	CcSEcCtD
Naltrexone—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000155	0.000542	CcSEcCtD
Naltrexone—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000155	0.000542	CcSEcCtD
Naltrexone—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000155	0.000542	CcSEcCtD
Naltrexone—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000155	0.000541	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000155	0.00335	CbGpPWpGaD
Naltrexone—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000155	0.00054	CcSEcCtD
Naltrexone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000154	0.00054	CcSEcCtD
Naltrexone—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000154	0.00054	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000154	0.00334	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000154	0.00334	CbGpPWpGaD
Naltrexone—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000154	0.000539	CcSEcCtD
Naltrexone—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000154	0.000539	CcSEcCtD
Naltrexone—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000154	0.000538	CcSEcCtD
Naltrexone—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000154	0.000537	CcSEcCtD
Naltrexone—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000154	0.000537	CcSEcCtD
Naltrexone—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000153	0.000535	CcSEcCtD
Naltrexone—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.000535	CcSEcCtD
Naltrexone—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000153	0.000535	CcSEcCtD
Naltrexone—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000153	0.000533	CcSEcCtD
Naltrexone—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000152	0.000533	CcSEcCtD
Naltrexone—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000152	0.000533	CcSEcCtD
Naltrexone—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000152	0.000533	CcSEcCtD
Naltrexone—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000152	0.000531	CcSEcCtD
Naltrexone—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000152	0.000531	CcSEcCtD
Naltrexone—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000151	0.000529	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000151	0.000529	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000151	0.00327	CbGpPWpGaD
Naltrexone—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000151	0.000526	CcSEcCtD
Naltrexone—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.00015	0.000525	CcSEcCtD
Naltrexone—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.00015	0.000523	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.00015	0.000523	CcSEcCtD
Naltrexone—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000149	0.000522	CcSEcCtD
Naltrexone—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000149	0.000521	CcSEcCtD
Naltrexone—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000149	0.000521	CcSEcCtD
Naltrexone—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000149	0.000521	CcSEcCtD
Naltrexone—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000149	0.000521	CcSEcCtD
Naltrexone—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000149	0.00052	CcSEcCtD
Naltrexone—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000149	0.000519	CcSEcCtD
Naltrexone—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000149	0.000519	CcSEcCtD
Naltrexone—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000149	0.000519	CcSEcCtD
Naltrexone—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000148	0.000518	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000148	0.000518	CcSEcCtD
Naltrexone—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000148	0.000517	CcSEcCtD
Naltrexone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000148	0.000517	CcSEcCtD
Naltrexone—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000148	0.000517	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000148	0.0032	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000148	0.00319	CbGpPWpGaD
Naltrexone—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000147	0.000515	CcSEcCtD
Naltrexone—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000147	0.000515	CcSEcCtD
Naltrexone—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.000515	CcSEcCtD
Naltrexone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000147	0.000513	CcSEcCtD
Naltrexone—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000147	0.000513	CcSEcCtD
Naltrexone—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000147	0.000513	CcSEcCtD
Naltrexone—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000147	0.000513	CcSEcCtD
Naltrexone—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000147	0.000512	CcSEcCtD
Naltrexone—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000146	0.000512	CcSEcCtD
Naltrexone—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000146	0.000512	CcSEcCtD
Naltrexone—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000146	0.000511	CcSEcCtD
Naltrexone—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000146	0.00051	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000146	0.00316	CbGpPWpGaD
Naltrexone—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000146	0.00051	CcSEcCtD
Naltrexone—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000145	0.000508	CcSEcCtD
Naltrexone—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000145	0.000508	CcSEcCtD
Naltrexone—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000145	0.000508	CcSEcCtD
Naltrexone—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000145	0.000507	CcSEcCtD
Naltrexone—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000145	0.000507	CcSEcCtD
Naltrexone—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000145	0.000506	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000144	0.000505	CcSEcCtD
Naltrexone—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000144	0.000504	CcSEcCtD
Naltrexone—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000144	0.000502	CcSEcCtD
Naltrexone—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000144	0.000502	CcSEcCtD
Naltrexone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000144	0.000502	CcSEcCtD
Naltrexone—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000144	0.000502	CcSEcCtD
Naltrexone—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000143	0.000501	CcSEcCtD
Naltrexone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000143	0.000501	CcSEcCtD
Naltrexone—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000143	0.000499	CcSEcCtD
Naltrexone—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000143	0.000499	CcSEcCtD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000143	0.00309	CbGpPWpGaD
Naltrexone—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000142	0.000497	CcSEcCtD
Naltrexone—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000142	0.000497	CcSEcCtD
Naltrexone—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000142	0.000496	CcSEcCtD
Naltrexone—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000142	0.000496	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000142	0.000495	CcSEcCtD
Naltrexone—Rash—Stavudine—acquired immunodeficiency syndrome	0.000142	0.000495	CcSEcCtD
Naltrexone—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000142	0.000495	CcSEcCtD
Naltrexone—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000142	0.000495	CcSEcCtD
Naltrexone—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000141	0.000494	CcSEcCtD
Naltrexone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000494	CcSEcCtD
Naltrexone—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000141	0.000493	CcSEcCtD
Naltrexone—Headache—Stavudine—acquired immunodeficiency syndrome	0.000141	0.000492	CcSEcCtD
Naltrexone—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000141	0.000492	CcSEcCtD
Naltrexone—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000141	0.000491	CcSEcCtD
Naltrexone—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00014	0.000491	CcSEcCtD
Naltrexone—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00014	0.000491	CcSEcCtD
Naltrexone—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.00014	0.00049	CcSEcCtD
Naltrexone—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00014	0.00049	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00014	0.00303	CbGpPWpGaD
Naltrexone—Rash—Abacavir—acquired immunodeficiency syndrome	0.00014	0.000488	CcSEcCtD
Naltrexone—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000139	0.000487	CcSEcCtD
Naltrexone—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000139	0.000487	CcSEcCtD
Naltrexone—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000139	0.000487	CcSEcCtD
Naltrexone—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000139	0.000487	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000139	0.00301	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000139	0.00301	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000139	0.00301	CbGpPWpGaD
Naltrexone—Headache—Abacavir—acquired immunodeficiency syndrome	0.000139	0.000485	CcSEcCtD
Naltrexone—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000139	0.000484	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000138	0.000483	CcSEcCtD
Naltrexone—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000138	0.000483	CcSEcCtD
Naltrexone—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000138	0.000483	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000138	0.00299	CbGpPWpGaD
Naltrexone—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000137	0.00048	CcSEcCtD
Naltrexone—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000137	0.000479	CcSEcCtD
Naltrexone—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000137	0.000478	CcSEcCtD
Naltrexone—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000136	0.000476	CcSEcCtD
Naltrexone—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000136	0.000476	CcSEcCtD
Naltrexone—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000136	0.00294	CbGpPWpGaD
Naltrexone—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000136	0.000474	CcSEcCtD
Naltrexone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000136	0.000474	CcSEcCtD
Naltrexone—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000473	CcSEcCtD
Naltrexone—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000473	CcSEcCtD
Naltrexone—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000135	0.000473	CcSEcCtD
Naltrexone—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000472	CcSEcCtD
Naltrexone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000471	CcSEcCtD
Naltrexone—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000134	0.000469	CcSEcCtD
Naltrexone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000134	0.000468	CcSEcCtD
Naltrexone—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000134	0.000468	CcSEcCtD
Naltrexone—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000134	0.000467	CcSEcCtD
Naltrexone—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000133	0.000466	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000133	0.000465	CcSEcCtD
Naltrexone—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000133	0.00288	CbGpPWpGaD
Naltrexone—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000133	0.000464	CcSEcCtD
Naltrexone—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000132	0.00287	CbGpPWpGaD
Naltrexone—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000132	0.000462	CcSEcCtD
Naltrexone—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000132	0.000461	CcSEcCtD
Naltrexone—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000131	0.00046	CcSEcCtD
Naltrexone—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000131	0.000459	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000131	0.000458	CcSEcCtD
Naltrexone—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000131	0.000457	CcSEcCtD
Naltrexone—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.00013	0.000456	CcSEcCtD
Naltrexone—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00013	0.000455	CcSEcCtD
Naltrexone—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.000455	CcSEcCtD
Naltrexone—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.000454	CcSEcCtD
Naltrexone—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.00013	0.000454	CcSEcCtD
Naltrexone—Pain—Ritonavir—acquired immunodeficiency syndrome	0.00013	0.000454	CcSEcCtD
Naltrexone—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.00013	0.000454	CcSEcCtD
Naltrexone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00013	0.000454	CcSEcCtD
Naltrexone—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000129	0.000451	CcSEcCtD
Naltrexone—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000129	0.000449	CcSEcCtD
Naltrexone—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000127	0.000444	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000127	0.000444	CcSEcCtD
Naltrexone—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000126	0.000442	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000126	0.000441	CcSEcCtD
Naltrexone—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000126	0.000441	CcSEcCtD
Naltrexone—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000126	0.00044	CcSEcCtD
Naltrexone—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000125	0.000438	CcSEcCtD
Naltrexone—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000125	0.000437	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000125	0.00271	CbGpPWpGaD
Naltrexone—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000125	0.000437	CcSEcCtD
Naltrexone—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000125	0.000437	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000125	0.0027	CbGpPWpGaD
Naltrexone—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000434	CcSEcCtD
Naltrexone—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000124	0.000434	CcSEcCtD
Naltrexone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000124	0.000434	CcSEcCtD
Naltrexone—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000124	0.000434	CcSEcCtD
Naltrexone—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000433	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000123	0.00267	CbGpPWpGaD
Naltrexone—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000123	0.00043	CcSEcCtD
Naltrexone—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000123	0.00043	CcSEcCtD
Naltrexone—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000123	0.00043	CcSEcCtD
Naltrexone—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000123	0.00266	CbGpPWpGaD
Naltrexone—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000122	0.000428	CcSEcCtD
Naltrexone—UGT1A1—Metabolism—TAT—acquired immunodeficiency syndrome	0.000122	0.00264	CbGpPWpGaD
Naltrexone—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000121	0.000424	CcSEcCtD
Naltrexone—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000121	0.000424	CcSEcCtD
Naltrexone—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000121	0.000423	CcSEcCtD
Naltrexone—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000121	0.000422	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000121	0.00261	CbGpPWpGaD
Naltrexone—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.00012	0.000421	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00012	0.000421	CcSEcCtD
Naltrexone—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.00012	0.00042	CcSEcCtD
Naltrexone—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00012	0.00042	CcSEcCtD
Naltrexone—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.00012	0.000419	CcSEcCtD
Naltrexone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.00012	0.000419	CcSEcCtD
Naltrexone—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.00012	0.000418	CcSEcCtD
Naltrexone—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000119	0.000417	CcSEcCtD
Naltrexone—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000119	0.000417	CcSEcCtD
Naltrexone—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000118	0.000412	CcSEcCtD
Naltrexone—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000117	0.00254	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000117	0.00254	CbGpPWpGaD
Naltrexone—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000117	0.00041	CcSEcCtD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000117	0.00254	CbGpPWpGaD
Naltrexone—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000116	0.000406	CcSEcCtD
Naltrexone—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000116	0.000406	CcSEcCtD
Naltrexone—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000116	0.000405	CcSEcCtD
Naltrexone—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000116	0.000404	CcSEcCtD
Naltrexone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000116	0.000404	CcSEcCtD
Naltrexone—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000115	0.000404	CcSEcCtD
Naltrexone—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000115	0.000402	CcSEcCtD
Naltrexone—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000115	0.00248	CbGpPWpGaD
Naltrexone—Rash—Indinavir—acquired immunodeficiency syndrome	0.000115	0.0004	CcSEcCtD
Naltrexone—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000114	0.0004	CcSEcCtD
Naltrexone—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000114	0.000398	CcSEcCtD
Naltrexone—Headache—Indinavir—acquired immunodeficiency syndrome	0.000114	0.000398	CcSEcCtD
Naltrexone—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000113	0.000397	CcSEcCtD
Naltrexone—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000112	0.000393	CcSEcCtD
Naltrexone—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.000391	CcSEcCtD
Naltrexone—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000112	0.00242	CbGpPWpGaD
Naltrexone—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000387	CcSEcCtD
Naltrexone—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000385	CcSEcCtD
Naltrexone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000385	CcSEcCtD
Naltrexone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000109	0.000381	CcSEcCtD
Naltrexone—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.000381	CcSEcCtD
Naltrexone—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000109	0.00235	CbGpPWpGaD
Naltrexone—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000109	0.000379	CcSEcCtD
Naltrexone—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000378	CcSEcCtD
Naltrexone—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000378	CcSEcCtD
Naltrexone—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000108	0.000377	CcSEcCtD
Naltrexone—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000376	CcSEcCtD
Naltrexone—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000376	CcSEcCtD
Naltrexone—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.000375	CcSEcCtD
Naltrexone—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000106	0.00229	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000106	0.00229	CbGpPWpGaD
Naltrexone—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000366	CcSEcCtD
Naltrexone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.000365	CcSEcCtD
Naltrexone—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000363	CcSEcCtD
Naltrexone—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000104	0.00225	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000104	0.00224	CbGpPWpGaD
Naltrexone—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.000362	CcSEcCtD
Naltrexone—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000361	CcSEcCtD
Naltrexone—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000361	CcSEcCtD
Naltrexone—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000359	CcSEcCtD
Naltrexone—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000359	CcSEcCtD
Naltrexone—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000102	0.000356	CcSEcCtD
Naltrexone—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.0001	0.000351	CcSEcCtD
Naltrexone—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.00035	CcSEcCtD
Naltrexone—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.0001	0.000349	CcSEcCtD
Naltrexone—Pruritus—Lamivudine—acquired immunodeficiency syndrome	9.86e-05	0.000345	CcSEcCtD
Naltrexone—Nausea—Delavirdine—acquired immunodeficiency syndrome	9.75e-05	0.000341	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	9.73e-05	0.00211	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	9.7e-05	0.0021	CbGpPWpGaD
Naltrexone—Dizziness—Saquinavir—acquired immunodeficiency syndrome	9.66e-05	0.000338	CcSEcCtD
Naltrexone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	9.65e-05	0.000337	CcSEcCtD
Naltrexone—Rash—Ritonavir—acquired immunodeficiency syndrome	9.57e-05	0.000335	CcSEcCtD
Naltrexone—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	9.57e-05	0.000334	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.56e-05	0.00207	CbGpPWpGaD
Naltrexone—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	9.54e-05	0.000333	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.53e-05	0.00206	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	9.52e-05	0.00206	CbGpPWpGaD
Naltrexone—Headache—Ritonavir—acquired immunodeficiency syndrome	9.51e-05	0.000332	CcSEcCtD
Naltrexone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	9.29e-05	0.000325	CcSEcCtD
Naltrexone—Dizziness—Lamivudine—acquired immunodeficiency syndrome	9.22e-05	0.000322	CcSEcCtD
Naltrexone—Rash—Saquinavir—acquired immunodeficiency syndrome	9.22e-05	0.000322	CcSEcCtD
Naltrexone—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	9.21e-05	0.000322	CcSEcCtD
Naltrexone—Headache—Saquinavir—acquired immunodeficiency syndrome	9.16e-05	0.00032	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.15e-05	0.00198	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.15e-05	0.00198	CbGpPWpGaD
Naltrexone—Nausea—Ritonavir—acquired immunodeficiency syndrome	9.02e-05	0.000315	CcSEcCtD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.96e-05	0.00194	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.96e-05	0.00194	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	8.93e-05	0.00193	CbGpPWpGaD
Naltrexone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	8.86e-05	0.00031	CcSEcCtD
Naltrexone—Rash—Lamivudine—acquired immunodeficiency syndrome	8.79e-05	0.000307	CcSEcCtD
Naltrexone—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	8.78e-05	0.000307	CcSEcCtD
Naltrexone—Headache—Lamivudine—acquired immunodeficiency syndrome	8.73e-05	0.000305	CcSEcCtD
Naltrexone—Nausea—Saquinavir—acquired immunodeficiency syndrome	8.68e-05	0.000303	CcSEcCtD
Naltrexone—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.65e-05	0.00187	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	8.62e-05	0.00187	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.39e-05	0.00182	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.35e-05	0.00181	CbGpPWpGaD
Naltrexone—Nausea—Lamivudine—acquired immunodeficiency syndrome	8.28e-05	0.000289	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.27e-05	0.00179	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.13e-05	0.00176	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.13e-05	0.00176	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.05e-05	0.00174	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.02e-05	0.00174	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.02e-05	0.00174	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.85e-05	0.0017	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.85e-05	0.0017	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.58e-05	0.00164	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.25e-05	0.00157	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.13e-05	0.00154	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.13e-05	0.00154	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.09e-05	0.00153	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.06e-05	0.00153	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.81e-05	0.00147	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.78e-05	0.00147	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.78e-05	0.00147	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.71e-05	0.00145	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.64e-05	0.00144	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.64e-05	0.00144	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.41e-05	0.00139	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	6.28e-05	0.00136	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.19e-05	0.00134	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.14e-05	0.00133	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.13e-05	0.00133	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.09e-05	0.00132	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.03e-05	0.0013	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.03e-05	0.0013	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.97e-05	0.00129	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.88e-05	0.00127	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.65e-05	0.00122	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	5.59e-05	0.00121	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.57e-05	0.00121	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.43e-05	0.00117	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.38e-05	0.00117	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.34e-05	0.00116	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.11e-05	0.00111	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.05e-05	0.00109	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.97e-05	0.00108	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.95e-05	0.00107	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.89e-05	0.00106	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.8e-05	0.00104	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.8e-05	0.00104	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.76e-05	0.00103	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.59e-05	0.000993	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.55e-05	0.000985	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.52e-05	0.000978	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.48e-05	0.00097	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.21e-05	0.000912	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.21e-05	0.000912	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.19e-05	0.000907	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.13e-05	0.000894	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.79e-05	0.00082	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.65e-05	0.000791	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.6e-05	0.000779	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.56e-05	0.000771	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.56e-05	0.000771	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.55e-05	0.000768	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.29e-05	0.000713	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.22e-05	0.000697	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.2e-05	0.000694	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.16e-05	0.000683	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.11e-05	0.000673	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	3.1e-05	0.000671	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.89e-05	0.000625	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.82e-05	0.000611	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.71e-05	0.000586	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.67e-05	0.000578	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.63e-05	0.000569	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.44e-05	0.000528	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.39e-05	0.000517	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—acquired immunodeficiency syndrome	2.13e-05	0.00046	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.08e-05	0.000451	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.9e-05	0.000412	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.89e-05	0.00041	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.67e-05	0.000361	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.66e-05	0.000359	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.41e-05	0.000305	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.4e-05	0.000304	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.12e-05	0.000242	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.81e-06	0.000212	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	9.75e-06	0.000211	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.29e-06	0.000179	CbGpPWpGaD
